While the interim results of the new coronavirus (Corona 19) vaccine, which is being developed by U.S. pharmaceutical company Whitea and Germany's Bioentech, have been announced, attention is being paid to the German couple from the second generation of Turkish immigrants who founded Bioentec.
According to the British daily Guardian on the 9th (local time), Biotech was jointly established by Ughur Sahin (55) and Ozzlem Turge (53) in 2008. All of them were born in the 1960s to a Turkish migrant worker's family who came to Germany in search of work.
Sahin was born in Turkey, moved to Cologne, Germany at the age of four, and Turing was born in Germany. The couple, who have German citizenship and a teenage daughter, met and married at a German university in 2002. The wedding was also held in laboratory gowns, and both of them were so absorbed in research that they resumed their research after registering their marriage to the government office on the day of the wedding. "The success of these couples is the achievement of Turkish immigrants who have been considered low-educated for decades," said Tagas Spiegel, a Berlin-based magazine.
According to the Guardian, Sahin said in an interview with German media, "When I read an article about Corona 19 in January this year, I told my wife, 'Germany will also close school in April.' In fact, Germany closed schools in March, when the company had already developed 20 vaccine candidate materials.
Shares of Bioentech jumped 23.4 percent on the day, with its market capitalization jumping to $21.9 billion. In particular, this includes $55 million (about 61.6 billion won) in investment from Microsoft founder Bill Gates. Thus, the Sahin and the Turridge couple are expected to become rich.
In fact, Biotech has already signed an agreement with Gates' private charity "Bill and Mulinda Gates Foundation" in September last year to develop human immunodeficiency viruses (HIV) and tuberculosis programs. "Bioentech's innovative mRNA-based approach provides a way to develop new immuno-based treatments that can drastically reduce global incidence," said Linda Stewart, vice chairman of the organization.
Meanwhile, Huiza has been working with Bioentech since 2018 to develop flu vaccines. Huiza paid $185 million ($206.3 billion) to Bioentech in advance to develop the Corona 19 vaccine. When development is completed, $533 million (KRW 594.4 billion) will be paid additionally.They've gone to the present heroes who help us stop the hard times from the corona.
copyright(c) 2015 Gyeonggido Office of Education. All rights reserved
